Clinical Trials Arena on MSN
CellProthera sets the scene for Phase III stem cell therapy trial
The biotech will soon evaluate the safety and efficacy of its regenerative cardiovascular stem cells, coined ProtheraCytes, in a Phase III trial.
Global cardiac surgery device market will grow from $21.1B in 2025 to $30.8B by 2032, driven by advances in imaging, ...
Healthgrades has announced the recipients of the 2026 Patient Safety Excellence Awards which recognize hospitals that provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results